Free press releases distribution network?

Agency / Source: Aciont, Inc.

Check Ads Availability|e-mail Article


Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!



Aciont® to Present on Visulex™ Technologies at the 4th Ocular & Drug Discovery Conference - Dr. Kongnara Papankorn and Dr. Sarah Molokhia will present on behalf of Aciont Inc at the Global Technology Community’s 4th Ocular & Drug Discovery Conference, February 27-28, in Las Vegas, NV - Aciont.com
Aciont® to Present on Visulex™ Technologies at the 4th Ocular & Drug Discovery Conference

 

PRZOOM - /newswire/ - Salt Lake City, UT, United States, 2012/01/10 - Dr. Kongnara Papankorn and Dr. Sarah Molokhia will present on behalf of Aciont Inc at the Global Technology Community’s 4th Ocular & Drug Discovery Conference, February 27-28, in Las Vegas, NV - Aciont.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Aciont Inc. announced today that both Kongnara Papangkorn, Research Director and Sarah Abdulla Molokhia, Scientific Research Consultant, will present on Aciont’s Visulex technologies at the Global Technology Community’s 4th Ocular & Drug Discovery Conference, February 27-28, 2012, in Las Vegas, NV. The Visulex system aims to eliminate frequent, painful injections to the eye while improving patient experience, ease of use, and accessibility to treatments currently on the market. The patient-friendly drug delivery applicator allows for treatment by nurses or potentially patients themselves.

Dr. Papangkorn’s presentation is entitled,“A Non-Invasive Topical Application Device for Treatment of Intermediate and Posterior Segment Eye Diseases.” The presentation discusses Aciont’s passive diffusion-based ocular drug delivery system (Visulex-P) and its potential to improve treatment of certain serious eye diseases such as intermediate and posterior uveitis.

Dr. Molokhia’s presentation is entitled,“Transscleral Iontophoresis for Macromolecules,” which will discuss the success of in vivo macromolecule delivery to the posterior eye tissues using iontophoresis (a mild electrical field). The device (Visulex-I) has shown promising results during in vitro and in vivo pharmacokinetics studies as well as in vivo real time magnetic resonance imaging studies. “Our research demonstrates the ability for Visulex-I to deliver drug amounts within the same order of magnitude reported using intravitreal injections, potentially revolutionizing the treatment of sight-threatening diseases, particularly age-related macular degeneration,” explains Dr. Molokhia.

Program note: John Higuchi, Aciont’s CEO, may substitute as the presenter on behalf of Dr. Molokhia in the event she is unable to attend the conference.

Aciont Inc. (aciont.com) is a specialty biopharmaceutical company endeavoring to become the world leader in commercializing localized, non-invasive (topical passive diffusion-based and iontophoretic), controlled and sustained release back of the eye therapeutics for sight threatening diseases such as severe uveitis, diabetic macular edema and age-related macular degeneration. Aciont’s goal is to provide ophthalmologists substantially greater freedom in treating and/or preventing chronic eye diseases through optimal drug dosing and improved patient/physician compliance. Aciont is located in Salt Lake City, Utah.

Contact
John Higuchi, CEO - Aciont, Inc.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma/BioTech/Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Aciont, Inc.

 
 

Availability: All Metropolitan Area

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma/BioTech/Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Aciont® to Present on Visulex™ Technologies at the 4th Ocular & Drug Discovery Conference

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
|
Contact: Jillian Conrad - Aciont.com 
801-359-3461 admin[.]aciont.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Aciont, Inc. securities in any jurisdiction including any other companies listed or named in this release.

Pharma/BioTech/Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY



Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!




Read Latest Press Releases From Aciont, Inc. / Company Profile


Read Pharma/BioTech/Nutrition Most Recent Related Press Releases:

BD Expands Suite of Blood Culture Offerings with New BD BACTEC™ Standard Aerobic & Standard Anaerobic Plastic Bottles
Twist Bioscience Collaborates with Synbio Technologies to Supply Long DNA to Customers
FDA Grants Priority Review and Breakthrough Therapy Designation for Zelboraf (vemurafenib) in Erdheim-Chester Disease with BRAF V600 Mutation
Ipsen Receives Positive CHMP Opinion for Approval of Xermelo® (telotristat Ethyl)
BD Receives FDA 510(k) Clearance for New Immunological Diagnostic System
Positive Phase III Results for Genentech’s Emicizumab in Hemophilia A Published in The New England Journal of Medicine
Somatuline® Autogel® 120 Mg Receives Japanese Approval for A New Indication for the Treatment of Gastro-entero-pancreatic Neuroendocrine Tumors
OTC Topical Drugs Market Size will Grow Profitably in the Near Future 2017-2025 Finds PMR
Bioinformatics Market Size to Expand at 20.4% CAGR through 2020 Reports Persistence Market Research
Australia Nitric Acid Market Expected to Reach at Value of $1.3B by 2024 End Says PMR

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
Find business coaching, life coaching, executive coaching and corporate coaching, best selling coaching books, ...



PREMIUM Members


Visit  La Bella Bakery Artisan Bakery Arizona

Visit  MagLar, Inc.

Visit  NAKIVO, Inc.







 
  ©2017 PRZOOM — Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today